

**Amendments to the Claims**

Please amend the claims as follows in the Listing of Claims. The Listing of Claims shall replace any previous listing. No new matter has been added.

**Listing of Claims**

1. (Currently Amended) A pharmaceutical composition comprising a safe and efficient amount of osteogenic growth peptide or OGP, a safe and efficient amount of granulocyte colony-stimulating factor or G-CSF and a pharmaceutically acceptable carrier, wherein the molar ratio of OGP to G-CSF is from 0.25:1 to ~~[[100]]~~ 20:1.
2. (Original) The pharmaceutical composition of Claim 1 further comprising a component selected from the group consisting of GM-CSF, EPO, IL-2, or the combination thereof.
3. (Previously Presented) The pharmaceutical composition of Claim 1 wherein the OGP is selected from the group consisting of human OGP, its pharmaceutically acceptable salts, and the combination thereof.
4. (Original) The pharmaceutical composition of Claim 1, wherein the molar ratio of OGP to G-CSF is from 1:1 to 20:1.
5. (Canceled)
6. (Original) The pharmaceutical composition of Claim 1, wherein the formulation of the pharmaceutical composition is injection, or lyophilized powder.
7. (Previously Presented) The pharmaceutical composition of Claim 3, wherein the human OGP has the amino acid sequence of SEQ ID NO. 1.
8. (Currently Amended) A method for preparing a pharmaceutical composition, comprising the following steps: mixing the OGP, G-CSF and a pharmaceutically acceptable carrier, thereby obtaining the pharmaceutical composition, wherein the molar

ratio of OGP to G-CSF is from 0.25:1 to [[100]] 20:1.

9. (Original) The method of Claim 8 wherein the molar ratio of OGP to G-CSF is from 1:1 to 20:1.

10. (Original) The method of Claim 8 wherein the formulation of the pharmaceutical composition is injection, or lyophilized powder.

11. (Canceled)